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Objectives: The autogenous arteriovenous access for chronic hemodialysis is recommended over the prosthetic access
because of its longer lifespan. However, more than half of the United States dialysis patients receive a prosthetic access.
We conducted a systematic review to summarize the best available evidence comparing the two accesses types in terms of
patient-important outcomes.
Methods:We searched electronic databases (MEDLINE, EMBASE, Cochrane CENTRAL, Web of Science and SCOPUS)
and included randomized controlled trials and controlled cohort studies. We pooled data for each outcome using a
random effects model to estimate the relative risk (RR) and its associated 95% confidence interval (CI). We estimated
inconsistency caused by true differences between studies using the I2 statistic.
Results: Eighty-three studies, of which 80 were nonrandomized, met eligibility criteria. Compared with the prosthetic
access, the autogenous access was associated with a significant reduction in the risk of death (RR, 0.76; 95% CI,
0.67-0.86; I2  48%, 27 studies) and access infection (RR, 0.18; 95% CI, 0.11-0.31; I2  93%, 43 studies), and a
nonsignificant reduction in the risk of postoperative complications (hematoma, bleeding, pseudoaneurysm and steal
syndrome, RR 0.73; 95% CI, 0.48-1.16; I2  65%, 31 studies) and length of hospitalization (pooled weighted mean
difference –3.8 days; 95% CI, –7.8 to 0.2; P .06). The autogenous access also had better primary and secondary patency
at 12 and 36 months.
Conclusion: Low-quality evidence from inconsistent studies with limited protection against bias shows that autogenous
access for chronic hemodialysis is superior to prosthetic access. ( J Vasc Surg 2008;48:34S-47S.)Several studies have demonstrated that autogenous
arteriovenous access for chronic hemodialysis has longer
patency compared with prosthetic access.1,2 The National
Kidney Foundation Dialysis Outcomes Quality Initiative
(NKF KDOQI) advocates the use of autogenous access if
possible in all clinical scenarios.3
Nevertheless, the prosthetic access is widely used in
the United States, to the extent that in 2002, it repre-
sented 80% of accesses used in prevalent dialysis patients
compared with 24% in Europe.4 The increased use of
prosthetic access may be attributed to putative benefits in
some patients such as women and the elderly,5-7 the
availability of off-the-shelf conduit for placement, the
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34Shigher reimbursement associated with prosthetic access
placement, the ability to cannulate and use the prosthetic
access without waiting for maturation, more amenability
of the prosthetic access to thrombectomy, and the high
nonmaturity rate of the autogenous access.8-10 To our
knowledge, no published systematic reviews have evalu-
ated the two types of accesses in terms of patient-impor-
tant outcomes other than patency, such as death and
sepsis.
To aid physicians and patients in making informed
choices about the placement and management of hemodi-
alysis access, the Society for Vascular Surgery created a
multispecialty committee to produce clinical practice
guidelines based on the best available evidence. The aim of
this review is to inform the development of these guidelines
and compare the two types of accesses in terms of patient-
important outcomes.
METHODS
The report of this protocol-driven systematic review
was approved by the Society for Vascular Surgery and
adheres to the standards for reporting Meta-analysis Of
Observational Studies in Epidemiology (MOOSE).11Whenever possible, we used the nomenclatures and def-
show
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for Reports Dealing with Arteriovenous Hemodialysis
Accesses” by the Society for Vascular Surgery.12
Eligibility criteria. We sought to include randomized
controlled trials (RCTs) and cohort studies that compared
a group of patients that have an autogenous access with a
concurrent comparison group that had a prosthetic access.
The outcomes of interest were death, access infection,
postoperative complications, the duration of hospitaliza-
tion due to access complications, and patency. We included
studies regardless of their language, size, or duration of
patient follow-up.
Study identification. An expert reference librarian
designed and conducted the electronic search strategy with
input from study investigators with expertise in conducting
systematic reviews. To identify eligible studies, we searched
electronic databases (MEDLINE, EMBASE, Cochrane
CENTRAL, Web of Science and SCOPUS) through
March 2007. The search strategy, which was tailored to
each database, included controlled vocabulary and text
words describing vascular access in hemodialysis (including
terms for renal disease, methods of vascular access, and
access type). We also sought references from experts, bib-
liographies of included studies, and the ISI Science Citation
Index for publications that cited included studies (details
are available from the authors upon request).
References were uploaded in a Web-based software
package developed for systematic review data management
(SRS, TrialStat Corporation, Ottawa, Ontario Canada).
Paired reviewers working independently screened all ab-
stracts and titles for eligibility. References that were
deemed potentially relevant were retrieved in full text and
uploaded for full text evaluation against eligibility criteria.
Disagreements were resolved by consensus (the two re-
viewers discussed the study and reached a consensus) and
by arbitration (a third reviewer adjudicated the study) when
disagreement continued.
Data collection. Teams of reviewers working inde-
Fig 1. Flow chartpendently and in duplicates and using standardized formsextracted descriptive, methodologic, and outcome data
from all eligible studies. Outcomes were extracted from
text, tables, and graphs (survival curves). Study quality was
assessed using the Newcastle-Ottawa Scale for assessing the
quality of observational studies.13 We sent e-mails to au-
thors of all included studies to obtain missing data and to
verify the presence of any collected but unreported data.
When e-mail addresses were not published (particularly for
older studies), we searched for authors’ newer publications
or attempted to contact their institutions to obtain current
e-mail addresses.
Statistical analysis
Meta analyses. We pooled relative risks (RR) from
each trial using the DerSimonian-Laird random effects
model and estimated the 95% confidence intervals (CIs) for
each outcome.14 Patency rates were converted to dichoto-
mous outcomes for specific time periods (12 and 36
months).6 In all analyses in this review, a RR1.0 indicates
benefit from autogenous access vs prosthetic access. We
assessed the heterogeneity among studies using the I2
statistic, which represents the proportion of variability
across studies that is not due to chance or random error but
rather is due to real differences in study design, population,
or interventions.15 I2 values of 25%, 50%, and 75% indicate
low, moderate, and high heterogeneity, respectively. Statis-
tical analysis was conducted by using ComprehensiveMeta-
Analysis 2 software (Biostat Inc, Englewood, NJ; 2005).
Subgroup analyses. A priori hypotheses to explain
potential heterogeneity in the direction and magnitude of
effect among included studies were patients’ age (children
vs adult, age 65 vs 65 years), gender, diabetes status,
the presence of peripheral vascular disease, the location of
the access (upper arm vs lower arm), and whether studies
reported outcomes per patient or per access and whether
patients were incidental or prevalent hemodialysis patients.
Also, we conducted meta-regression to determine whether
study quality or the length of study follow-up (predictor
s study selection.variables) affected patency outcomes (dependent variable).
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First author, year
Patients,
No.
Mean
Age, y
Incidental/
prevalent
Autogenous
Location Vessels
Haimov,17 1980 126a NR Inc Upper arm Brachiocephalic
Mangiarotti,18 1983 205 NR NR Forearm, upper arm, thigh 36.96 brachial, 7.04 radial; 22.88 cephalic
vein, 7.04 basilic, 14.08 other veins
ATordoir,19 1983 149 49 Inc Forearm Radiocephalic
Louridas,20 1984 152 43 NR Forearm, upper arm Radiocephalic, brachiocephalic
Winsett,21 1985 508 45 Prev Forearm Radiocephalic, brachiocephalic
Kherlakian,22 1986 200 52 Inc Forearm Radiocephalic
Zibari,23 1988 230 52 Mixed Forearm, upper arm Brachiocephalic, radiocephalic
Filiptsev,24 1989 84 NR NR Multiple (shoulder, upper
arm, thigh)
NR
Nazzal,25 1990 125 37 Inc Forearm, upper arm Radiocephalic, brachiocephalic
Sands,26 1992 111 64 NR NR NR
Churchill,27 1992 347 18 Inc NR NR
Tang,28 1992 63 50 Prev NR NR
Sanabia,29 1993 74 9 Inc Upper arm, forearm Radiocephalic, ulnar basilic, antecubital
Taylor,30 1993 1897 NR Inc NR NR
Al-Wakeel,31 1994 105 42 Inc Forearm, upper arm Radiocephalic, brachiocephalic
Bender,32 1994 68 62 Mixed Elbow, wrist Radiocephalic, brachiocephalic
Chalabi,33 1994 84 51 Inc NR Saphenous vein
Coburn,34 1994 81 65 Inc Upper arm Brachiobasilic
Riordan,35 1994 464 48 Inc Forearm Radiocephalic
Chazan,36 1995 117 57 Prev NR NR
Kim,37 1995 172 43 NR NR NR
Sands,38 1995 107 NR Inc NR NR
Tedoriya,39 1995 113 47 Inc Forearm, upper arm Radiocephalic, ulnar basilic, snuffbox,
brachiocephalic
Vaccaro,40 1995 276 56 Prev Forearm Radiocephalic
Enzler,41 1996 414 44 Mixed Forearm, upper arm NR
Herzig,42 1997 391 58 Inc Multiple NR
Hodges,43 1997 350 59 Inc Forearm, upper arm Radiocephalic, brachiocephalic
Miller,44 1997 76 64 Inc Forearm, upper arm Cephalic, brachial, radial, basilic
Sparks,45 1997 427 54 Inc Forearm, upper arm Radiocephalic, brachiocephalic,
brachiocubital
Woods,46 1997 784 66 Mixed NR NR
Bay,47 1998 2792 60 Prev Upper arm (6.4%),
forearm (20.6%)
NR
Miranda,48 1998 1308a NR Prev Forearm or upper arm Cephalic or basilic veins
Berardinelli,49 1998 348 72 Inc Forearm, upper arm Radiocephalic, brachiocephalic
Bosman,50 1998 131 60 Inc Forearm, upper arm, thigh Denatured homologous vein graft, straight
radiocephalic, loop radiocephalic,
brachiocephalic, femoral.
Cante,51 1998 51 74 Inc Forearm NR
Jenkins,52 1980 56 NR Inc Forearm, upper arm, thigh Radiocephalic, brachiocephalic, femoral
Matsuura,53 1998 98 61 Inc Upper arm Brachioaxillary, basilic vein transposition
Obialo,54 1998 36 42 NR Forearm Radio cephalic
Silva,55 1998 172 63 Inc Forearm, upper arm NR
Wang,56 1998 131 60 Prev Multiple NR
Agarwal,57 1999 32 56 Prev NR NR
Turnbull,58 1999 166 NR Inc Forearm, upper arm Radiocephalic, brachiocephalic, brachiobasilic
Ascher,59 2000 247 69 Inc Forearm, upper arm Radiocephalic, brachiocephalic, brachiobasilic
Astor,5 2000 833 63 Prev NR NR
Rodriguez,60 2000 544 56 NR Forearm, upper arm Radiocephalic, brachiocephalic,
humerobasilar
Staramos,61 2000 114 78 Inc Forearm, upper arm Radiocephalic, brachiocephalic, basilic
transposition
62Brunori, 2000 203 68 Inc Forearm, upper arm Radiocephalic, brachiocephalic
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Prosthetic
F/U, d
Study
designLocation Vessels
Forearm, upper arm, thigh Radiocephalic, brachiocephalic, femoral NR Prosp
Forearm, upper arm, thigh 22 brachial, 1 arterial stump from prosthesis; 8 brachial,
8 basilic, 3 cephalic, 4 other veins
1740 Retro
Forearm, upper arm, thigh Radiocephalic, brachiocephalic, saphenofemoral 1145 Prosp
Forearm, upper arm, thigh Brachial to axillary, axillary to femoral, axillary to
basilic, axillary to cephalic
NR Retro
Forearm Radiocephalic, brachiocephalic, brachiocubital 730 Retro
Upper arm, thigh Brachiocephalic, brachiobasilic, femoral 1095 Retro
Forearm, upper arm, thigh Radiocephalic, brachioaxillary, femoral, femoral-
popliteal
NR Retro
Multiple (shoulder, upper
arm, thigh)
NR NR Prosp
Upper arm Brachioaxillary 300 Prosp
NR NR 180 Retro
NR NR NR Prosp
NR NR 300 Prosp
Forearm, upper arm,
thigh, neck
Radiocephalic, brachiocephalic, brachiojugular, femoral NR Retro
NR NR NR Retro
Forearm, upper arm Radiocephalic, brachiocephalic 1825 Retro
Forearm, upper arm NR 1095 Retro
Upper arm Humeroaxillary, humerobasilic, humerocephalic 1825 Retro
Upper arm Brachiobasilic, Brachioaxillary, Brachiocephalic NR Retro
Forearm, upper arm, thigh Radiocephalic, brachiocephalic, femoral NR Retro
NR NR 425 Prosp
NR NR 510 Retro
NR NR 772 Retro
NR NR 6570 Retro
Upper arm PTFE 730 Retro
Forearm, upper arm, thigh NR NR Retro
Multiple NR NR Retro
Forearm, upper arm, thigh NR NR Retro
Upper arm Brachiocephalic loop or straight graft 455 Retro
Upper arm Loop brachial-cephalic/basilic or a bridge
radial-cephalic/basilic construction.
1026 Retro
NR NR 365 Retro
Forearm straight (14.7%),
forearm loop (24.8%),
upper arm straight
(26.1%), upper arm
loop (3.8%), femoral
graft (2.3%)
NR 365 Prosp
Forearm, upper arm,
thigh, chest
Cephalic, basilic, femoral, axillary 180 Retro
Forearm, upper arm Radiocephalic, brachiocephalic 5475 Retro
Forearm, thigh PTFE: loop radiocephalic, straight radiocephalic,
femoral
326 RCT
Forearm NR 730 Retro
Forearm, upper arm, thigh Radiocephalic, brachiocephalic, femoral NR Prosp
Upper arm Brachioaxillary NR Retro
Upper arm Brachiocephalic 365 Prosp
Forearm, upper arm Radiocephalic, brachioaxillary 401 Prosp
Multiple NR 180 Prosp
NR NR 252 Prosp
Forearm, upper arm Radiocephalic, brachiocephalic, straight, loop NR Retro
NR NR 270 Retro
NR NR 395 Retro
Upper arm, thigh Humerocephalic, humerobasilic, femoro-femoral 2532 Retro
Forearm, upper arm, thigh Brachiocephalic, brachioaxillary, femoral 1095 ProspNR NR NR Retro
ot blin
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ses to test the effect of including studies in which investi-
gators determined study outcomes clinically or from ad-
ministrative databases (eg, billing codes). Using billing/
administrative data to determine outcomes reduces the bias
caused by outcome assessors not being blinded but intro-
duces misclassification bias (intentional or unintentional
erroneous coding). We conducted sensitivity analysis with
and without the assumption that denatured homologous
vein grafts and saphenous vein grafts are considered autog-
Table I. Continued.
First author, year
Patients,
No.
Mean
Age, y
Incidental/
prevalent
Dhingra,63 2001 4469 59 Prev NR
Gibson,64 2001 152 56 Mixed NR
Gibson,65 2001 1583 66 Inc NR
Oliver,66 2001 195 57 Inc Upp
Dixon,67 2002 204 56 Inc Fore
Lawrence,68 2002 71 57 Prev NR
Pastan,69 2002 7403 58 Prev NR
Ridao-Cano,70 2002 872 56 Inc Fore
Saxena,71 2002 218 48 Prev NR
Sheth,72 2002 34 13 Inc Fore
Valentine,73 2002 72 57 Inc Upp
Johnson,74 2002 207  50 NR Wris
Baaran,75 2003 2950 38 Inc Fore
Cernadas,76 2003 60 61 Inc Upp
Choi,77 2003 97 54 NR Fore
Culp,78 1995 267 62 Inc Fore
Fisher,79 2003 197 61 Inc Fore
Shenoy,80 2003 1110 59 Prev NR
Xue,81 2003 25226 67 Mixed NR
Yu,82 2003 82 61 Prev NR
Di Iorio,83 2004 2201 62 Prev NR
Hazinedaroglu,84
2004
30 59 Inc Thig
Kizilisik,85 2004 93 61 Inc Fore
Perera,86 2004 209 57 Inc Upp
Polkinghorne,87
2004
2632 18 Inc NR
Akoh,88 2005 151 62 Inc Fore
Astor,89 2005 206 59 Inc NR
Fitzgerald,90 2005 146 56 Inc Upp
Kawecka,91 2005 722 44 Mixed Upp
ex
Manns,92 2005 239 63 NR Fore
Ramage,93 2005 114 12 Inc Upp
Rooijens,94 2005 383 60 Inc Fore
Ates,95 2006 920 42 Inc Fore
Roca-tey,96 2006 89 63 Prev Upp
Woo,97 2007 329 65 Prev Upp
Keuter,98 2008 105 63 Prev Upp
F/U, Follow-up, Inc, incidental dialysis patients; NR, not reported; Prev, p
retrospective; RCT, randomized controlled trial.
aThis is the number of accesses; number of patients is not reported.
bCommunication with author indicates that patients and care givers were nenous accesses. We also explored the robustness of ourresults by analyzing the data with accounting for censoring
in time-to-event outcomes according to the method of
Pramar et al.16
RESULTS
Study identification. Our search and selection pro-
cedures yielded 995 potentially eligible references, of
which 99 proved eligible and 83 provided data for meta-
analyses (Fig 1). Study characteristics are summarized in
Autogenous
ocation Vessels
NR
NR
NR
Brachiocephalic, brachiobasilic transposition
upper arm Radiocephalic, brachiocephalic
NR
NR
upper arm Radiocephalic, basiocephalic
NR
upper arm, thigh Radiocephalic, brachiocephalic, femoral
Brachial-based arteriovenous fistula
ow NR
upper arm Radiocephalic, brachiocephalic
Transposed brachiobasilic
upper arm Radiocephalic, brachiocephalic,
brachiobasilic, transposed, non-
transposed
upper arm NR
upper arm Radiocephalic, brachiocephalic
NR
NR
NR
NR
Femoral vein transposition
upper arm Radiocephalic, brachiocephalic,
brachiobasilic
Radiocephalic mainly, brachiocephalic.
Basilic vein used in 4
NR
upper arm Brachiocephalic, radiocephalic
NR
Brachiocephalic, brachiobasilic,
brachiomedian
lower
ties
Radiocephalic, brachiocephalic and
brachiobasilic
upper arm Radiocephalic, brachiocephalic
Radiocephalic, brachiocephalic
Radiocephalic
upper arm Radiocephalic, brachiocephalic
Radiocephalic, brachiocephalic
NR
Brachial-basilic
t dialysis patients; Pros, prospective; PTFE, polytetrafluoroethylene; Retro,
ded, data collectors were blinded, and allocation was concealed.L
er arm
arm,
arm,
arm,
er arm
t, elb
arm,
er arm
arm,
arm,
arm,
h
arm,
er arm
arm,
er arm
er and
tremi
arm,
er arm
arm
arm,
er arm
er arm
er arm
revalenTable I.5,17-98 The chance adjusted inter-reviewer agree-
rm lo
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(range, 0.61-1.00). These studies enrolled 69,816 par-
ticipants (mean size, 850 patients; mean age, 55 years;
mean follow-up, 2.8 years). Authors from 26 of the 83
included studies (31%) responded to our e-mail queries
and provided missing data. Seven studies were translated
to English.1,24,99,40,100-102
Methodologic quality. Three studies were open ran-
domized trials,50,94,98 and 80 were observational studies,
of which 56 had a retrospective cohort design and 24 had a
prospective cohort design. Allocation was concealed and
data collectors were blinded in one of the randomized
trials.98 The distribution of the Newcastle-Ottawa quality
scale components that describe the quality of observational
Table I. Continued.
Prosthetic
Location V
NR NR
NR NR
NR NR
Upper arm Brachioaxillary
Forearm Forearm loop radiocepha
NR NR
NR NR
Forearm, upper arm Radiocephalic, brachiocep
NR NR
Forearm, upper arm, thigh Radiocephalic, brachiocep
Upper arm, forearm Radiocephalic, brachiocep
NR NR
Upper arm NR
Upper arm PTFE brachioaxillary brid
Forearm, upper arm Brachioaxillary, mediocub
Forearm, upper arm NR
Forearm, upper arm, thigh Forearm loop, upper arm
NR NR
NR NR
NR NR
NR NR
Thigh Superficial femoral artery
femoral vein
Forearm, upper arm Straight, loop
Upper arm Brachial mainly, radial. O
vein
NR NR
Forearm, upper arm,
chest, thigh
Forearm straight, forearm
femoral, axillary
NR NR
Forearm Brachiobasilic, brachiocep
Upper and lower arm NR
Upper arm Brachiocephalic
Forearm, upper arm, thigh Radiocephalic, brachiocep
Forearm Brachiocephalic
Upper arm Brachioaxillary, brachioce
Upper arm, thigh Brachiocephalic, femoral
Upper arm NR
Forearm Brachial antecubital foreastudies are summarized in Table II. Only 46% of the studiescontrolled for at least one possible confounder in cohort
selection or analysis. The proportion lost to follow-up was
10% in only 19% of the studies. Only 20% of the studies
reported a funding source. Inter-reviewer agreement (
statistic) of the different components of quality averaged
0.70 (range, 0.53-1.00).
Meta-analyses. The autogenous access was associated
with a significant reduction in the risk of death (RR, 0.76;
95% CI, 0.67-0.86; I2 48%; 27 studies; Fig 2) and access
infection (RR, 0.18; 95% CI, 0.11-0.31; I2  93%; 43
studies; Fig 3). The autogenous access was also associated
with a nonsignificant reduction in the risk of postoperative
complications of access placement other than infection,
including hematoma, bleeding, pseudoaneurysm, and steal
F/U, d
Study
design
730 Prosp
511 Retro
340 Retro
600 Retro
1825 Prosp
NR Retro
260 Retro
, straight, loop grafts 1825 Retro
1460 Prosp
, femoral 3650 Retro
, straight or loop 180 Prosp
360 Prosp
1160 Retro
tula 730 Retro
ephalic or basilic vein 545 Retro
365 Prosp
, thigh loop 780 Retro
730 Retro
365 Retro
365 Prosp
730 Retro
henous or common 237 Prosp
600 Retro
brachial/axillary, basilic 1095 Retro
1095 Retro
, brachioaxillary, 567 Retro
810 Retro
, brachiomedian 430 Retro
570 Retro
NR Retro
, femoral 7300 Retro
365 RCT
c 1825 Retro
354 Prosp
860 Retro
op 365 RCTbessels
lic
halic
halic
halic
ge fis
ital, c
loop
to sap
utflow
loop
halic
halic
phalisyndrome (RR, 0.73; 95% CI, 0.48-1.12; I2  65%, 31
random-effects pooled relative risk (RR) of death.
10% 65 (81)
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access complications was lower in patients who had autog-
enous accesses (pooled weighted mean difference –3.8
days; 95% CI –7.8 to 0.2; P  .06; 3 studies).
Primary and secondary patency rates at 12 and 36
months were significantly higher in the autogenous than in
the prosthetic access. RRs for access failure without inter-
ventions to maintain or re-establish patency were 0.72
(95% CI, 0.65-0.80) at 12 months and 0.67 (95% CI,
0.58-0.78 at 36 months. RRs for access failure including
interventions to maintain or re-establish patency were 0.83
(95% CI, 0.70-0.99) at 12 months and 0.67 (95% CI,
0.61-0.74) at 36 months.
Subgroup analyses. One of the a priori established
analyses to explain heterogeneity of results is autogenous
access location (upper arm vs lower arm, both compared
with prosthetic access at any location). We found a signifi-
cant access location–access complications interaction (P 
.02) demonstrating that the magnitude of benefit from
autogenous access vs prosthetic access is significantly more
when autogenous access was placed in the lower arm. There
were no significant death–access location, access infection–
access location or patency–access location interactions (P
.60, P  .18, and P  .33, respectively).
Only two studies compared the autogenous upper arm
access with a prosthetic lower arm access (prosthetic looped
forearm access).90,98 Pooling the outcomes of the two
studies (a total of 249 patients) demonstrates that the
death. The vertical line indicates no treatment effect; the
% confidence intervals (CIs) for each study; diamonds,Fig 2. Meta-analysis of the effect of access type on the risk of
squares and horizontal lines, point estimates and associated 95Table II. Distribution of components of the Newcastle-
Ottawa quality scale of cohort studies
Component
Studies,
No. (%)
Cohort selection
Study cohorts are representative of the typical patients
encountered in practice
Yes 77 (96)
No or not reported 3 (4)
Exposure ascertainment (type of access)
Adequate (clinical exam or chart review) 63 (79)
Inadequate (self-report or not reported) 17 (21)
Studies confirmed that the access was functional at
the outset
Yes 20 (25)
No or not reported 60 (75)
Cohort comparability
Studies controlled for possible confounders in cohort
selection or analysis
Controlled for 2 or more confounders 30 (37)
Controlled for one confounder 7 (9)
Did not control for confounders 43 (54)
Outcome
Outcome assessment
Adequate (physical exam, chart review, record
linkage)
56 (70)
Inadequate (self-report, not reported) 24 (30)
The length of follow-up adequate to assess outcomes
equal or 12 months 47 (59)
12 months 33 (41)
Proportion lost to follow-up
10% 15 (19)placement of autogenous access in the upper arm is associ-
ccess
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95% CI, 0.07-0.83) and nonsignificant trends for better
12-month primary (RR, 0.88; 95% CI, 0.72-1.07) and
secondary (RR, 0.81; 95% CI, 0.54-1.20) patency. Patency
at 24 months was only reported by Fitzgerald et al90 and
was similar between the two accesses. Both studies reported
the upper arm placement of autogenous access to be asso-
ciated with fewer complications and to require fewer inter-
ventions to maintain patency.
Interactions based on patient type (incidental vs
prevalent hemodialysis) for outcomes of death, access
infections, access complications, and patency were all
nonsignificant (P  .4, P  .77, P  .43, and P  .33,
respectively).
Several studies reportedoutcomes by access rather thanby
Fig 3. Meta-analysis of the effect of access type on the r
effect; squares and horizontal lines, point estimates and
diamonds, random-effects pooled relative risk (RR) of apatient, a unit-of-analysis challenge given the likely correlationof outcomes for accesses in the same patient. However, the
results in studies reporting patency, access complications, and
access infection, per patient vs per access, were not different (P
 .80, P .43 and P .33, respectively).
There were no significant patency-gender or patency-
age (65 or65 years) interactions. A significant patency-
age interaction (pediatric vs adults) was found in a single,
small pediatric study that showed the autogenous access
patency in children was inferior to that of the prosthetic
access at 12 and 36 months (P  .02 and P  .07,
respectively); however, autogenous patency regained supe-
riority at 60 months of follow-up.72 Subgroup analyses are
summarized in Table III.
Meta-regression revealed that neither study quality nor
the length of study follow-up explained the between-study
access infection. The vertical line indicates no treatment
ciated 95% confidence intervals (CIs) for each study;
infection.isk of
assovariability in patency reported across studies. In terms of
elativ
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longer patency36 and lower mortality63 than the prosthetic
access in patients with and without diabetes. Hence, it
appears that the presence of diabetes should not affect the
choice of access.
Sensitivity analyses. Sensitivity analyses are summa-
rized in Table IV. The exclusion of studies in which the
autogenous access was denatured homologous vein graft
or saphenous vein grafts and the exclusion of studies that
used administrative and billing databases to determine
outcomes caused no significant change in any of the
results.
Because the shortest and longest follow-up times for
study participants, which are the key variables in the
adjustment for censoring of time-to-event data reported
in graphic form, were either not reported or were similar
in both study arms, adjustments for censoring were
either not feasible or led to proportionate decrements of
the sizes of both study arms, slightly widening the CIs
without affecting the estimates of RR for any of the
outcomes examined or their statistical significance (data
not shown).
DISCUSSION
We conducted a systematic review and meta-analyses
to compare the autogenous and prosthetic accesses for
Fig 4. Meta-analysis of the effect of access type on the
line indicates no treatment effect; squares and horizontal
(CIs) for each study; diamonds, random-effects pooled rchronic hemodialysis in terms of patient-important out-comes. We found that very low-quality evidence103 with
significant heterogeneity suggests that the autogenous
access of hemodialysis is superior to the prosthetic access
in terms of the risks of death, access infection, and
primary and secondary patency. Overall, there were in-
sufficient data to identify a subgroup to which the overall
conclusions do not apply, although subgroup analyses
were underpowered.
Limitations and strengths. Although systematic re-
views and meta-analyses comparing autogenous vs pros-
thetics accesses exist, 6,10 to our knowledge this is the
first comprehensive review to assess patient-important
outcomes other than patency. Efforts to reduce bias such
as author contact, a review of the literature by two
independent reviewers, and explicit quality assessment
strengthen inferences from this review.
The main limitation of this review is the nonrandomized
design of most of the included studies, which meant that the
choice of access type was based on surgeons’ preference,
patients’ comorbidities, and other unmeasured yet potentially
important confounders. Although this inherent bias in obser-
vational studies canbe remedied to some extent by controlling
for factors that can affect study outcomes in either selecting
cohorts or in analysis, we found that many studies did not
control for these factors, rendering the cohort that received
prosthetic access to include more patients with diabetes, pa-
f access complications other than infection. The vertical
point estimates and associated 95% confidence intervals
e risk (RR) of access complications.risk o
lines,tients with peripheral vascular disease, and older patients. This
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Volume 48, Number 5S Murad et al 43Sbias in selection has likely overestimated the benefit noted in
patients who received the autogenous access. Moreover, the
proportion of studies that contributed to each of the out-
comes in this review was low; thus, reporting bias has likely
affected the benefits noted with autogenous access placae-
Table III. Subgroup analyses
Variable Studies, No
Death
Upper arm autogenous vs prosthetic 6
Lower arm autogenous vs prosthetic 3
Incidental HD patients 19
Prevalent HD patients 5
Access infection
Upper arm autogenous vs prosthetic 11
Lower arm autogenous vs prosthetic 5
Studies that used access data 29
Studies that used patient data 13
Incidental HD patients 30
Prevalent HD patients 5
Access complications
Upper arm autogenous vs prosthetic 9
Lower arm autogenous vs prosthetic 5
Studies that used access data 21
Studies that used patient data 10
Incidental HD patients 22
Prevalent HD patients 4
Primary patency at 12 months
Upper arm autogenous vs prosthetic 14
Lower arm autogenous vs prosthetic 11
Males 2
Females 2
Old (65) 2
Young (65) 2
Studies that used access data 28
Studies that used patient data 12
Incidental HD patients 28
Prevalent HD patients 6
Primary patency at 36 months
Upper arm autogenous vs prosthetic 8
Lower arm autogenous vs prosthetic 4
Studies that used access data 13
Studies that used patient data 5
Incidental HD patients 15
Prevalent HD patients 6
Secondary patency at 12 months
Upper arm autogenous vs prosthetic 9
Lower arm autogenous vs prosthetic 7
Pediatric studies 1
Adult studies 22
Studies that used access data 18
Studies that used patient data 5
Incidental HD patients 15
Prevalent HD patients 4
Secondary patency at 36 months
Upper arm autogenous vs prosthetic 8
Lower arm autogenous vs prosthetic 6
Pediatric studies 1
Adult studies 18
Studies that used access data 16
Studies that used patient data 3
Incidental HD patients 12
Prevalent HD patients 4
CI, Confidence interval; HD, hemodialysis; RR, relative risk.ment.104Other limitations relate to extracting survival data from
graphs and to the inconsistency of the taxonomy in the
included studies, which underscores the need for standard-
ized nomenclature.12 In addition, one study33 could not be
retrieved and was extracted directly from a previously pub-
RR (95% CI) P (interaction test)
0.68 (0.25-1.83) 0.55
0.46 (0.21-1.01)
0.72 (0.58-0.89) 0.74
0.76 (0.60-0.97)
0.21 (0.12-0.36) 0.17
0.10 (0.04-0.24)
0.21 (0.12-0.35) 0.33
0.34 (0.15-0.74)
0.22 (0.11-0.47) 0.77
0.26 (0.09-0.70)
1.22 (0.48-3.10) 0.02
0.20 (0.06-0.68)
0.69 (0.42-1.11) 0.43
1.06 (0.41-2.71)
0.86 (0.48-1.53) 0.43
0.56 (0.23-1.35)
0.70 (0.56-0.88) 0.09
0.94 (0.73-1.20)
0.50 (0.39-0.65) 0.64
0.65 (0.22-1.88)
0.57 (0.25-1.32) 0.56
0.89 (0.25-3.15)
0.68 (0.60-0.77) 0.51
0.78 (0.60-1.03)
0.75 (0.65-0.87) 0.16
0.63 (0.52-0.77)
0.87 (0.66-1.14) 0.78
0.80 (0.48-1.34)
0.65 (0.54-0.78) 0.08
0.83 (0.67-1.01)
0.75 (0.59-0.94) 0.16
0.59 (0.48-0.73)
0.70 (0.51-0.96) 0.07
0.99 (0.82-1.20)
6.67 (1.13-41.46) 0.02
0.82 (0.62-0.99)
0.82 (0.66-0.97) 0.45
0.95 (0.68-1.32)
0.88 (0.69-1.13) 0.70
0.97 (0.63-1.50)
0.73 (0.60-0.90) 0.33
0.65 (0.58-0.73)
1.69 (0.63-4.53) 0.07
0.67 (0.60-0.76)
0.67 (0.59-0.75) 0.80
0.71 (0.46-1.09)
0.72 (0.60-0.85) 0.33
0.61 (0.46-0.81).lished systematic review.6
ative r
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Although the available evidence is consistent with pre-
vious recommendations for using autogenous accesses for
hemodialysis, the current review highlights that this infer-
ence is derived from very low-quality evidence. That is,
large studies with better protection against bias—preferably
randomized trials measuring patient important out-
comes—are necessary to make recommendations with con-
fidence because these may substantially change the esti-
mates reported here. Patient and surgeon preferences, cost
considerations, and clinical circumstances should inform
the choice of access for specific patients. The accompanying
practice guideline document includes the practical implica-
tion of this evidence from the standpoint of the expert
members of the committee of the Society for Vascular
Surgery.
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Table IV. Sensitivity analysis
Variable
Death
Pooled estimate from all included studies
Excluding studies that used administrative data to assess outcom
Excluding DHV and saphenous vein grafts from autogenous gr
Primary patency at 12 months
Pooled estimate from all included studies
Excluding DHV and saphenous vein grafts from autogenous gr
Excluding studies that used administrative data to assess outcom
Adjustment for censoring applied
Adjustment for censoring not applied
Primary patency at 36 months
Pooled estimate from all included studies
Excluding studies that used administrative data to assess outcom
Adjustment for censoring applied
Adjustment for censoring not applied
Secondary patency at 12 months
Pooled estimate from all included studies
Excluding DHV and saphenous vein grafts from autogenous gr
Excluding studies that used administrative data to assess outcom
Adjustment for censoring applied
Adjustment for censoring not applied
Secondary patency at 36 months
Pooled estimate from all included studies
Adjustment for censoring applied
Adjustment for censoring not applied
CI, Confidence interval; DHV, denatured homologous vein grafts; RR, relOverall responsibility: MHMREFERENCES
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